Pharmaceuticals company Rubicon Research announced Q4FY26 & FY26 results Q4FY26 Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 5,139.15 million in Q4FY26, registering a strong YoY growth of 43.49% compared to Rs 3,581.47 million in Q4FY25, and a QoQ growth of 8.07% compared to Rs 4,755.29 million in Q3FY26. Total Income: Reached Rs 5,165.25 million, showcasing a YoY increase of 44.18% (from Rs 3,582.45 million in Q4FY25) and a QoQ increase of 7.76% (from Rs 4,793.16 million in Q3FY26). Profit Before Tax (PBT): Reported at Rs 986.87 million, up by 93.28% YoY from Rs 510.60 million in Q4FY25, and higher by 8.94% QoQ from Rs 905.86 million in Q3FY26. Net Profit After Tax (PAT): Stood at Rs 767.85 million, reflecting a massive YoY growth of 111.85% compared to Rs 362.45 million in Q4FY25, and a QoQ growth of 5.48% from Rs 727.97 million in Q3FY26. FY26 Consolidated Financial Highlights: Revenue from Operations: Grew by 36.57% YoY to Rs 17,539.56 million in FY26, compared to Rs 12,842.72 million in FY25. Total Income: Increased by 36.79% YoY to Rs 17,616.83 million, up from Rs 12,879.06 million in the previous financial year. Profit Before Tax (PBT): Stood at Rs 3,205.34 million, marking a 64.78% growth over Rs 1,945.23 million reported in FY25. Net Profit After Tax (PAT): Achieved a robust growth of 83.64% YoY, rising to Rs 2,467.35 million in FY26 from Rs 1,343.61 million in FY25. Q4FY26 Standalone Financial Highlights: Revenue from Operations: Reached Rs 3,898.78 million, increasing by 29.61% YoY (vs Rs 3,008.06 million in Q4FY25) and 29.22% QoQ (vs Rs 3,017.11 million in Q3FY26). Total Income: Stood at Rs 3,934.59 million, up by 25.80% YoY (vs Rs 3,127.75 million in Q4FY25) and 28.58% QoQ (vs Rs 3,060.12 million in Q3FY26). Profit Before Tax (PBT): Reported at Rs 941.85 million, up 74.64% YoY (vs Rs 539.31 million in Q4FY25) and 90.17% QoQ (vs Rs 495.28 million in Q3FY26). Net Profit After Tax (PAT): Stood at Rs 700.20 million, displaying a YoY growth of 73.89% (vs Rs 402.67 million in Q4FY25) and a QoQ growth of 88.32% (vs Rs 371.81 million in Q3FY26). FY26 Standalone Financial Highlights: Revenue from Operations: Grew to Rs 13,060.82 million, a rise of 21.63% from Rs 10,738.43 million in FY25. Total Income: Amounted to Rs 13,169.14 million, increasing by 20.43% from Rs 10,935.24 million in FY25. Profit Before Tax (PBT): Stood at Rs 2,527.79 million, marking a 13.21% YoY increase over Rs 2,232.80 million in FY25. Net Profit After Tax (PAT): Reported at Rs 1,881.65 million, registering a 12.31% YoY growth from Rs 1,675.37 million in FY25. Business Highlights: Segment-wise Performance: The company is primarily engaged in a single business segment, which is the "Sale of Pharmaceuticals products". Therefore, there are no other reportable operating segments. Dividend Announcement: The Board of Directors recommended a final dividend of Rs 1.50 per equity share of the face value of Rs 1 each for the financial year ended March 31, 2026. Initial Public Offering (IPO) & Listing: During FY26, the company successfully completed its IPO aggregating to Rs 13,775.00 million. This comprised a fresh issue of Rs 5,000.00 million and an Offer for Sale (OFS) of Rs 8,775.00 million. The equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on October 16, 2025. Consequently, General Atlantic Singapore RR PTE Ltd is no longer a holding company. International Expansion: The company incorporated a wholly-owned subsidiary, AdvaGen S A Company, in the Kingdom of Saudi Arabia on January 13, 2026, to engage in the trading of finished pharmaceutical products. Strategic Acquisition: The company entered into a definitive agreement to acquire a 65% stake in Arnna Lifesciences Limited for a total consideration of Rs 1,759.17 million. The acquisition was successfully completed post the financial year end, on April 30, 2026. Regulatory Update: The Goods and Services Tax (GST) authorities conducted an inspection at the company's premises located in Thane and Ambernath on January 30, 2026. The company extended full cooperation, and based on the assessment performed, no material discrepancies requiring adjustment in the financial results were identified, nor was any show-cause notice or order received. Result PDF